Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques

1. Front Matter

   Pages 1-8

   PDF

2. Treatment of helminth diseases — challenges and achievements

   • Satyavan Sharma

   Pages 9-100

3. Ribonucleotide reductase inhibitors as anticancer and antiviral agents

   • Eric J. Lien

   Pages 101-126

4. Pyrimidinones as biodynamic agents

   • Anil K. Saxena, Shradha Sinha

   Pages 127-160

5. Enzyme inhibitors of the renin-angiotensin system

   • Michael J. Antonaccio, John J. Wright

   Pages 161-191

6. Cooperative effects in drug-DNA interactions

   • W. David Wilson

   Pages 193-221

7. GABA-drug interactions

   • Richard W. Olsen

   Pages 223-241

8. Quinolones

   • Pramod M. Shah

   Pages 243-256

9. Risk assessment problems in chemical oncogenesis

   • G. H. Hottendorf

   Pages 257-272

10. The pharmacology of caffeine

    • M. J. Arnaud

    Pages 273-313

11. Mechanism of action of anxiolytic drugs

    • T. Mennini, S. Caccia, S. Garattini

    Pages 315-347

12. In Vitro Models for the Study of Antibiotic Activities

    • J. Blaser, S. H. Zinner

    Pages 349-381

13. Light and dark as a “drug”

    • Anna Wirz-Justice

    Pages 383-425

14. High resolution nuclear magnetic resonance spectroscopy of biological samples as an aid to drug development

    • J. K. Nicholson, Ian D. Wilson

    Pages 427-479

15. Back Matter

    Pages 481-526

    PDF

Volume 31 of "Progress in Drug Research" contains 13 articles, a sub­ ject index, an index for all articles that have been published so far in this series of monographs, as well as an author and subject index for all 31 volumes. The reviews in this volume are particularly concerned with the therapy of helminth diseases, with pyramidinones as biody­ namic agents, and with quinolones which are of interest in the treat­ ment of infections. For a deeper understanding of the pharmacokinet­ ic actions of modem drugs, the articles on cooperative binding of drug molecules to DNA, on in vitro models for the study of antibiotic activi­ ties, on inhibitors of the renin-angiotensin system, on GAB A-drug in­ teractions, and on the mechanism of action of anxiolytic drugs provide a wealth offacts and new findings. The pharmacology of caffeine is re­ viewed from the viewpoint of its role in combination with other phy­ siologically active substances, and the chapter on high resolution nuc­ lear magnetic resonance spectroscopy demonstrates the importance of this method in the development of new drugs. Finally, the article on light and dark touches border problems of the therapy of psychic dis­ orders. With these contributions, the authors aim to summarize latest achieve­ ments in important and actual fields of drug research. Researchers who are actively engaged in the same or in similar fields of research are sure to benefit from these efforts.

• Arzneimittel
• Arzneimittelforschung
• cancer
• drug
• drug development
• drug discovery
• drug research
• oncogenes
• pharmacology
• research

• Basel, Switzerland

  Ernst Jucker, Urs Meyer

Policies and ethics